BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 10450752)

  • 1. Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of Nos 5 and/or 7 and its possible relationship to replication error phenotype.
    Horiike S; Misawa S; Kaneko H; Sasai Y; Kobayashi M; Fujii H; Tanaka S; Yagita M; Abe T; Kashima K; Taniwaki M
    Leukemia; 1999 Aug; 13(8):1235-42. PubMed ID: 10450752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis.
    Christiansen DH; Andersen MK; Pedersen-Bjergaard J
    J Clin Oncol; 2001 Mar; 19(5):1405-13. PubMed ID: 11230485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Copy Number Variations in the Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients with del(5q) and/or -7/del(7q).
    Zhang R; Kim YM; Wang X; Li Y; Lu X; Sternenberger AR; Li S; Lee JY
    Int J Med Sci; 2015; 12(9):719-26. PubMed ID: 26392809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
    Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
    Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
    Side LE; Curtiss NP; Teel K; Kratz C; Wang PW; Larson RA; Le Beau MM; Shannon KM
    Genes Chromosomes Cancer; 2004 Mar; 39(3):217-23. PubMed ID: 14732923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
    Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
    Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. dic(5;17): a recurring abnormality in malignant myeloid disorders associated with mutations of TP53.
    Wang P; Spielberger RT; Thangavelu M; Zhao N; Davis EM; Iannantuoni K; Larson RA; Le Beau MM
    Genes Chromosomes Cancer; 1997 Nov; 20(3):282-91. PubMed ID: 9365836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of point mutations within the AML-1 gene in patients with MDS/AML and loss of chromosome 5q or 7.
    Ferrari T; Weber B; Pils S; Harbott J; Borkhardt A
    Ann Hematol; 2001 Feb; 80(2):72-3. PubMed ID: 11261327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unbalanced translocation der(5;17) resulting in a TP53 loss as recurrent aberration in myelodysplastic syndrome and acute myeloid leukemia with complex karyotype.
    Warnstorf D; Bawadi R; Schienke A; Strasser R; Schmidt G; Illig T; Tauscher M; Thol F; Heuser M; Steinemann D; Davenport C; Schlegelberger B; Behrens YL; Göhring G
    Genes Chromosomes Cancer; 2021 Jun; 60(6):452-457. PubMed ID: 33486841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High level of microsatellite instability but not hypermethylation of mismatch repair genes in therapy-related and secondary acute myeloid leukaemia and myelodysplastic syndrome.
    Sheikhha MH; Tobal K; Liu Yin JA
    Br J Haematol; 2002 May; 117(2):359-65. PubMed ID: 11972518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
    Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations.
    Stengel A; Kern W; Haferlach T; Meggendorfer M; Haferlach C
    Genes Chromosomes Cancer; 2016 Oct; 55(10):777-85. PubMed ID: 27218649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype.
    Ben-Yehuda D; Krichevsky S; Caspi O; Rund D; Polliack A; Abeliovich D; Zelig O; Yahalom V; Paltiel O; Or R; Peretz T; Ben-Neriah S; Yehuda O; Rachmilewitz EA
    Blood; 1996 Dec; 88(11):4296-303. PubMed ID: 8943866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The p53 gene in pediatric therapy-related leukemia and myelodysplasia.
    Felix CA; Hosler MR; Provisor D; Salhany K; Sexsmith EA; Slater DJ; Cheung NK; Winick NJ; Strauss EA; Heyn R; Lange BJ; Malkin D
    Blood; 1996 May; 87(10):4376-81. PubMed ID: 8639798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible association between tumor-suppressor gene mutations and hMSH2/hMLH1 inactivation in alveolar soft part sarcoma.
    Saito T; Oda Y; Kawaguchi K; Takahira T; Yamamoto H; Sakamoto A; Tamiya S; Iwamoto Y; Tsuneyoshi M
    Hum Pathol; 2003 Sep; 34(9):841-9. PubMed ID: 14562278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia.
    Christiansen DH; Andersen MK; Pedersen-Bjergaard J
    Leukemia; 2003 Sep; 17(9):1813-9. PubMed ID: 12970781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.
    Hong M; Hao S; Patel KP; Kantarjian HM; Garcia-Manero G; Yin CC; Medeiros LJ; Lin P; Lu X
    Cancer Genet; 2016 May; 209(5):205-14. PubMed ID: 27134073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 mutations in myelodysplastic syndrome.
    Misawa S; Horiike S
    Leuk Lymphoma; 1996 Nov; 23(5-6):417-22. PubMed ID: 9031070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
    Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
    Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
    J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.